ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,956.06
      0.01%
      US Tech 100
      20,523.60
      -0.04%
      Dow Jones
      43,433.12
      -0.43%
      Brent Oil
      72.145
      -0.24%
      Bitcoin
      86,256.92
      2.60%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Verona Pharma Plc (VRNA) Quote

      Verona Pharma Plc

      Verona Pharma Plc (VRNA)

      NASDAQ
      63.52
      1.13
      (1.81%)
      Closed February 27 4:00PM
      Delayed by 15 minutes
      65.9994
      2.48
      (3.90%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      65.9994
      Bid
      63.00
      Ask
      65.79
      Volume
      1,719,625
      62.67 Day's Range 65.7056
      0.00 52 Week Range 0.00
      Market Cap
      5.401B
      Previous Close
      62.39
      Open
      62.675
      Last Trade
      30
      @
      65.78
      Last Trade Time
      Financial Volume
      $ 110,443,376
      VWAP
      64.2253
      Average Volume (3m)
      -
      Shares Outstanding
      81,831,170
      Dividend Yield
      -
      PE Ratio
      0.00
      Earnings Per Share (EPS)
      -
      Revenue
      -
      Net Profit
      -54.37M

      About Verona Pharma Plc

      Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.veronapharma.com
      Headquarters
      London, Gbr
      Founded
      -
      Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRNA. The last closing price for Verona Pharma was $62.39. Over the last year, Verona Pharma shares have traded in a share price range of $ 0.00 to $ 0.00.

      Verona Pharma currently has 81,831,170 shares outstanding. The market capitalization of Verona Pharma is $5.11 billion.

      Ask ADVFN Intelligence (AI)

      Verona Pharma (VRNA) Options Flow Summary

      VRNA Options Flow

      Overall Flow

      Bearish

      Net Premium

      -4M

      Calls / Puts

      52.00%

      Buys / Sells

      216.67%

      OTM / ITM

      245.45%

      Sweeps Ratio

      31.58%

      VRNA Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      February 04 2025
      VRNA (1.81%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 07 2025
      VRNA (1.81%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 26 2024
      VRNA (1.81%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 25 2024
      VRNA (1.81%)

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
      Edgar (US Regulatory)
      November 14 2024
      VRNA (1.81%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 07 2024
      VRNA (1.81%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      VRNA - Frequently Asked Questions (FAQ)

      What is the current Verona Pharma share price?
      The current share price of Verona Pharma is $ 65.9994
      How many Verona Pharma shares are in issue?
      Verona Pharma has 81,831,170 shares in issue
      What is the market cap of Verona Pharma?
      The market capitalisation of Verona Pharma is USD 5.11B
      What is the 1 year trading range for Verona Pharma share price?
      Verona Pharma has traded in the range of $ 0.00 to $ 0.00 during the past year
      What is the reporting currency for Verona Pharma?
      Verona Pharma reports financial results in USD
      What is the latest annual profit for Verona Pharma?
      The latest annual profit of Verona Pharma is USD -54.37M
      What is the registered address of Verona Pharma?
      The registered address for Verona Pharma is ONE CENTRAL SQUARE, CARDIFF, LONDON, CF10 1FS
      What is the Verona Pharma website address?
      The website address for Verona Pharma is www.veronapharma.com
      Which industry sector does Verona Pharma operate in?
      Verona Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ENVBEnveric Biosciences Inc
      $ 2.27
      (92.37%)
      		135.42M
      PITAHeramba Electric PLC
      $ 0.694
      (88.08%)
      		100.75M
      PRCHPorch Group Inc
      $ 6.60
      (74.14%)
      		32.03M
      MULNMullen Automotive Inc
      $ 4.035
      (70.97%)
      		94.61M
      RENBRenovaro Inc
      $ 1.19
      (53.95%)
      		31.84M
      VEROVenus Concept Inc
      $ 0.326949
      (-39.45%)
      		1.97M
      SNDKSanDisk Corporation
      $ 46.705
      (-38.69%)
      		8.41M
      FLYWFlywire Corporation
      $ 11.045
      (-37.39%)
      		25.43M
      ILAGIntelligent Living Application Group Inc
      $ 0.5444
      (-33.61%)
      		478.24k
      ONVOOrganovo Holdings Inc
      $ 0.8499
      (-33.08%)
      		50.73M
      NVDANVIDIA Corporation
      $ 131.28
      (3.67%)
      		332.46M
      LCIDLucid Group Inc
      $ 2.255
      (-13.60%)
      		160.81M
      TRNRInteractive Strength Inc
      $ 1.2401
      (30.58%)
      		158.83M
      SMCISuper Micro Computer Inc
      $ 51.08
      (12.17%)
      		144.52M
      ENVBEnveric Biosciences Inc
      $ 2.27
      (92.37%)
      		135.42M

      VRNA Discussion

      View Posts
      powerwalker powerwalker 10 hours ago
      Roger, how are you feeling?
      👍️0
      Roger1 Roger1 15 hours ago
      Time of cc signals good news, imo
      👍️ 1 🙏 1 🤞 1
      powerwalker powerwalker 16 hours ago
      Given the quick move to $65.70 and subsequent halving of the gain, it seems MM's still seeking weak hands ... especially with tomorrow's CC before the market opens looming!
      👍️0
      Hoskuld Hoskuld 2 days ago
      Yes the high end is reasonable but the low end seems too low to credit. Zero new patients results in...16,000 patients = $250m per year, divided by 4 gives $62m for current quarter. If they add the bare minimum new patients during CQ (1,000 per week) then that would be average of 22,500 partients = $87m for CQ.
      👍️ 1
      MegaPirate61 MegaPirate61 2 days ago
      Estimated outlook for cq are between 65 and 90 million
      👍️0
      Hoskuld Hoskuld 3 days ago
      Roger, the average for Q4 was just over 1,000 patients per week with momentum building through the end of the year despite holidays. My estimate is, IMO, extremely conservative: no additional growth in new patients per week. This seems unlikely though so I expect those estimates of mine are low.
      👍️ 1
      Roger1 Roger1 4 days ago
      That would be awesome
      👍️0
      Hoskuld Hoskuld 4 days ago
      They had 16,000 patients on ohtuveyre as of 31DEC and I bet they announce that they have 25,000 patients as of 14FEB or 27,000 as of 24FEB.
      👍️ 1
      Roger1 Roger1 4 days ago
      Thanks. Looking forward to seeing quarterlies next week. Anyone speculate on uptake for January?
      👍️0
      Hoskuld Hoskuld 4 days ago
      Roger, buyout would be based on strength of market acceptance and uptake. BP should have already purchased for $100 per share, now the price will be $120 and will grow to $150-$200 as the next year plays out. A buyout could happen at any time - should happen at any time - but who knows?
      👍️ 1
      Roger1 Roger1 5 days ago
      How high does this go before getting taken out?
      👍️0
      powerwalker powerwalker 1 week ago
      I am interested in Verona's comments on filing an MAA with the EMA. Hopefully, they have or will be doing so soon.
      👍️0
      powerwalker powerwalker 2 weeks ago
      Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

      https://www.veronapharma.com/news/verona-pharma-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-corporate-update/
      👍️0
      powerwalker powerwalker 2 weeks ago
      Does anyone have any thoughts as to today's gain?
      👍️0
      Roger1 Roger1 3 weeks ago
      I can tell you that I've been off steroids for 3 weeks.
      👍️ 4 💥 1
      powerwalker powerwalker 3 weeks ago
      Hello, Roger:

      Is there any update on your condition which you would like to share?

      Thank you,
      powerwalker
      👍️0
      Monksdream Monksdream 1 month ago
      VRNA 1 yr
      👍️ 1
      MegaPirate61 MegaPirate61 1 month ago
      For 2025, Stan Druckenmiller
      made his long pick in the Robin Hood contest in Verona Pharma (VRNA). Verona's inhaled treatment for adults with chronic obstructive pulmonary disease (COPD) won FDA approval last June. On Jan. 8, it said fourth-quarter sales totaled $36 million in the multi-billion dollar blockbuster indication.
      👍️ 3
      powerwalker powerwalker 1 month ago
      Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

      https://finance.yahoo.com/news/verona-pharma-vrna-among-billionaire-201156030.html
      👍️ 2 😃 1
      MegaPirate61 MegaPirate61 1 month ago
      According to a msg board post the cfo said that their quarterly expenses were 50 million and sales were now break even and will soon be exceeding that.
      👍️ 2
      powerwalker powerwalker 1 month ago
      While it might not be making a presentation, Verona execs are at the JPM Healthcare Conference, partaking in meetings with future impact.
      👍️0
      MegaPirate61 MegaPirate61 2 months ago
      Posted a typo before the released shares that were already on the shelf total was 2.5 million shares not 12.5 mil
      👍️0
      Roger1 Roger1 2 months ago
      Yes
      👍️ 3
      Hoskuld Hoskuld 2 months ago
      Do you ascribe this improvement to ohtuvayre Roger? Congratulations!
      👍️ 1
      Roger1 Roger1 2 months ago
      Good news. I've been able to cut my Prednisone in half and hopefully eliminate it soon. Have found I can stretch my nebulizer treatments to Q6-7 from Q4. Will be interesting to see how much more improvement I can get b4 allergy season in Mar/April.
      👍️ 3
      powerwalker powerwalker 2 months ago
      Roger, what is going on with you and your ohtuvayre experience?

      We would like to hear about it.
      👍️ 2
      MegaPirate61 MegaPirate61 2 months ago
      Well they went and announced unofficial earnings on their own today. Also says they sold 12.5 million shares at an avg of 39.50 of so through Jeffries. Must have something else to announce at jpm?
      👍️ 1
      powerwalker powerwalker 2 months ago
      Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

      https://finance.yahoo.com/news/verona-pharma-reports-strong-ohtuvayre-110000636.html

      Sounds positive and noted the "J-code" that MegaPirate had emphasized. 👍️❤️
      👍️ 1
      powerwalker powerwalker 2 months ago
      Thank you, MegaPirate, for your reply.
      👍️ 1
      MegaPirate61 MegaPirate61 2 months ago
      I'm not Hoskuld but the company said in q n a session last earnings call that they would announce unaudited q4 2024 sales at jpm around Jan 12 to 14 if I remember right. We will all need to be patient here. A launch doesn't really start until the second quarter of having a j code which is just now active. We will have a better indication in a year of the early results.
      👍️0
      powerwalker powerwalker 2 months ago
      Hoskuld, do you think Verona will be invited to JP Morgan Healthcare Conference next week?
      👍️ 1
      Hoskuld Hoskuld 2 months ago
      That is so great Roger! How has ohtuvayre helped you? Easier to breathe? Less phlegm? Would you be willing to share your experience?
      👍️ 2
      powerwalker powerwalker 2 months ago
      Best of luck, Roger … it is time for a Christmas present for you and your elbow Virginians.

      Merry Christmas and a prosperous 2025.
      powerwalker
      👍️0
      Roger1 Roger1 2 months ago
      I can tell you the drug works for me. Acaria Pharma, specialty pharmacy filling rx's has thrown a wrench in the works by requiring Virginia patients to have additional Rx from the physician greatly increasing the time needed to fill. Ohtovayre patient portal reps are unaware. I've told 2 of them about it and emailed company but have not received any response. That was several weeks ago. I know my pulmonologist has prescribed it for several patients but I believe I may be the first to actually receive it.
      ,
      👍️ 3
      powerwalker powerwalker 2 months ago
      GIDDY-UP, VERONA, and all you hedge managers and investment bankers hitch yourselves to this rocket! It is ready to take-off!
      👍️ 1
      powerwalker powerwalker 3 months ago
      Let's go you, Investment advisors and hedge fund managers, get your valuation models going full tilt this weekend to calculate how quickly Verona can get to $100 ... and start buying!
      👍️0
      powerwalker powerwalker 3 months ago
      Hopefully, Verona will break the $40 ceiling and stay above it. Its performance deserves it.
      👍️ 1
      Hoskuld Hoskuld 3 months ago
      PW another claim by management is that this is the best pulmonary launch ever (by far.)
      👍️ 2
      powerwalker powerwalker 3 months ago
      Thank you, Hoskuld. I'll listen to one of the two tomorrow.
      👍️0
      Hoskuld Hoskuld 3 months ago
      I thought it was excellent PW: uptake is strong and docs are prescribing earlier in the disease cycle than anticipated which underscores the hunger for a differentiated therapy. Feedback from docs is good. Based on what he said, I expect the company will be cash flow positive by April.
      🎯 1 👍️ 2
      powerwalker powerwalker 3 months ago
      Any word on today's presentation?
      👍️0
      Roger1 Roger1 3 months ago
      Yes. Still waiting. Seems to be quite a process with Acaria pharmacy, Medicare, coinsurance. No idea where the process is at. I do know dr.s office has done all that's been asked. They are just as interested in any improvement as I am. Have a feeling I'm the guinea pig for this practice. <S>. I wonder if pharmacy is overwhelmed or is there some other reason. I'll let you know if I hear anything. Have a great day. 
      👍️ 3
      powerwalker powerwalker 3 months ago
      Good morning, Roger:

      Did the doctor's office get things right, so you are now on Ohtuvayre?

      If so, let us know how it is helping.
      👍️0
      powerwalker powerwalker 3 months ago
      Upcoming next week:

      Verona Pharma Announces December 2024 Investor Conference Participation
      Share

      LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

      Piper Sandler 36th Annual Healthcare Conference
      Date: Tuesday, December 3, 2024
      Time: 12:00 p.m. ET / 5:00 p.m. GMT
      Location: New York, NY

      7th Annual Evercore HealthCONx Conference
      Date: Wednesday, December 4, 2024
      Time: 3:00 p.m. ET / 8:00 p.m. GMT
      Location: Miami, FL

      A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

      https://www.veronapharma.com/news/verona-pharma-announces-december-2024-investor-conference-participation/
      👍️ 1
      MegaPirate61 MegaPirate61 3 months ago
      Probably a moot point. If it's a 200 billion dollar asset over time the most big pharma will pay is 20b. And they will take it sooner rather than later. Maybe within the next 2 yrs.
      👍️0
      Hoskuld Hoskuld 3 months ago
      Pricing is the US is pretty sweet - ROW not so much. If bicyclical then the motion will be elliptical.
      👍️0
      powerwalker powerwalker 3 months ago
      Does anyone have thoughts on yesterday's presentation? I read the slides and come away with the impression that Verona can serve 50% of the market with the focus on 80% of the HCPs intent to Prescribe Ohtuvayre.

      With $1.1 billion in sales for each !% or 86K patients, those are BIG numbers down the road as Mega and Hoskuld shared earlier this week.
      👍️ 1
      MegaPirate61 MegaPirate61 3 months ago
      Just search fintel Duquesne position of 680k shares you can validate this on multiple sites. Use ai in your searches lol
      👍️ 1
      powerwalker powerwalker 3 months ago
      Mega, article is behind a pay-wall for CNBC, so can't see it.

      I think he will buy more ... sooner, rather than later.
      👍️0
      Roger1 Roger1 3 months ago
      It is in process. Mixup at doctors office. Verona and Acaria have been very supportive and helpful. Should be straightened out today.
      👍️ 1

      Your Recent History

      NASDAQ
      VRNA
      Verona Pharma
      TG
      PR1T
      Amundi Luxembourg
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads